TITLE

MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes

AUTHOR(S)
Sormani, Maria Pia; De Stefano, Nicola
PUB. DATE
March 2014
SOURCE
Multiple Sclerosis Journal;Mar2014, Vol. 20 Issue 3, p280
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the potential role of magnetic resonance imaging (MRI) markers as primary outcome endpoint in multiple sclerosis (MS) Phase III randomized, controlled trials. It is inferred that the use of MRI as primary endpoints in trials testing anti-inflammatory drugs is advantageous to save costs and time, suggesting to advocate the practice on ethical grounds. The validity of MRI markers as surrogates of variables that have an impact of a MS patient's quality of life is explored.
ACCESSION #
94744218

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics